$32.59
Value $1.9B
HRMY and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$32.59
Value $1.9B
$270.30
Value $651B
Harmony Biosciences (HRMY) has a market value of $1.9B and Johnson & Johnson (JNJ) $651B. Over the last year, with dividends, HRMY moved -2.2% and JNJ +36.3%. The P/E is 10.6 for HRMY and 40.5 for JNJ. Dividend yield: HRMY none, JNJ 1.95%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
HRMY$1.9B
JNJ$651B
JNJ is 346 times HRMY
Revenue, 12 months
HRMY$989M
JNJ$99.3B
JNJ is 100 times HRMY
Net income, 12 months
HRMY$179M
JNJ$16.1B
JNJ is 90 times HRMY
Operating margin
HRMY22.2%
JNJ–
ROIC
HRMY15.3%
JNJ12.4%
2.9 points apart
P/E
HRMY10.6
JNJ40.5
JNJ is 3.8 times HRMY
Dividend yield
HRMY0.0%
JNJ2.0%
2.0 points apart
5-year return
HRMY-15.9%
JNJ+90.5%
106.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
HRMY-15.9%
JNJ+90.5%
| Period | HRMYWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -2.2%Price -2.2% | +36.3%Price +33.3% |
| 3 years since November 20, 2023 | +17.4%+5.5% a yearPrice +17.4% | +94.5%+24.8% a yearPrice +80.1% |
| 5 years since November 19, 2021 | -15.9%-3.4% a yearPrice -15.9% | +90.5%+13.8% a yearPrice +65.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
HRMYHarmony BiosciencesJNJJohnson & Johnson
| Price | $32.59 | $270.30 |
|---|---|---|
| Market value | $1.9B | $651B |
| Enterprise value (EV) | $1.3B | $679B |
| P/E | 10.6 | 40.5 |
| P/E, 5-year median | 15.2 | 21.9 |
| P/B | 1.8 | 8.0 |
| EV/EBIT | 5.8 | 38.3 |
| Free cash flow yield | 17.1% | 3.2% |
| Revenue, 12 months | $989M | $99.3B |
|---|---|---|
| Net income, 12 months | $179M | $16.1B |
| Free cash flow, 12 months | $323M | $20.6B |
| Earnings per share, 12 months | $3.03 | $6.59 |
| Revenue growth, year on year | 21.5% | 6.1% |
| Revenue growth a year, past | +40.3%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 74.0% | 67.6% |
|---|---|---|
| Operating margin | 22.2% | – |
| Net margin | 18.1% | 16.2% |
| ROIC | 15.3% | 12.4% |
| ROE | 19.1% | 19.7% |
| Cash | $771M | $17.2B |
|---|---|---|
| Total debt | $155M | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | 17.0× | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($651B) is about 345.6 times Harmony Biosciences ($1.9B), at today's prices.
Since November 19, 2021, HRMY's price moved -15.9% and JNJ's +65.7%. With dividends: HRMY -15.9% (-3.4% a year), JNJ +90.5% (+13.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Harmony Biosciences and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 10.6 for HRMY and 40.5 for JNJ. The median of the last five years was 15.2 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 18.1% for Harmony Biosciences and 16.2% for Johnson & Johnson, and the operating margin 22.2% and –. Revenue was $989M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.